Study of treatment patterns for acromegaly over time
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This study follows people with acromegaly to better understand how treatments are used in real life and how well they work over time. It may help improve future treatment choices by comparing outcomes across different care patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign an informed consent form
- You’re between 18 and 75 years old
- Your records show high growth hormone (GH) levels (at least once GH ≥ 2.5)
- Your records show imaging evidence of a pituitary tumor
- You do not have a rare form of GH release outside the pituitary and no pituitary cancer
- You do not currently have other active, complicated cancers or serious uncontrolled illnesses that could affect participation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
This study looks at how treatments for acromegaly affect how you function and move, especially in your hands, feet, and overall body structure. You may be asked to do assessments to understand changes over time and whether certain groups respond differently.
This trial tests if switching from a standard somatostatin analog to pasireotide can better control acromegaly in patients whose growth hormone and IGF-1 levels remain high. It aims to offer a more effective treatment option for those not responding well enough to initial therapy.
This early-phase trial tests a new investigational drug called MAR002 in healthy men. The goal is to see how safe the drug is and how the body handles it before moving to larger studies.
This study watches how patients with acromegaly respond to octreotide, a medication given as injections under the skin. Researchers will collect information about how well the treatment works and any side effects you experience.
Hear when a new Acromegaly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.